Ocular Therapeutix (OCUL) is a small biopharma focused on developing eye disease therapies utilizing its proprietary platform of bioresorbable implants. Ocular got on my radar after I saw this article from Jonathan Faison, and I wanted to add my take after thoroughly researching the company. I believe Ocular provides a lot of value to long-term investors at current price levels.
Ocular’s Platform Technology Is Targeting Several Huge Indications
Ocular is developing six different ophthalmology products, including several different extended-release products, utilizing its proprietary implant technology.
Figure 1: market Opportunities for Ocular’s Pipeline